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Abstract 
Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a relatively rare but serious side effect of 
bisphosphonate (BP)-based treatments. This retrospective study aimed to investigate the risk factors and predictive 
markers in cases where patients were refractory to a recommended conservative treatment offered in our hospital.
Patients and Methods: This single-center study collated the medical records of all patients treated for BRONJ bet-
ween 2004 and 2011. A complete medical history, including detailed questionnaires, was collected for all patients, 
focusing on identifying underlying risk factors, clinical features, location and bone marker levels of BRONJ.
Results: The mean BRONJ remission rate was 57.6%, and the median duration of remission was seven months. 
Eighteen patients (34.6%) had persistent or progressive disease with a recommended conservative treatment for 
BRONJ. Notably, urinary cross-linked N-terminal telopeptide of type 1 collagen (NTX) levels in those resistant to 
conservative treatment tended to be lower than in patients that healed well.
Conclusions: We confirm that a significant proportion of BRONJ sufferers are refractory to a recommended con-
servative treatment and find that anticancer drugs, periodontal disease, the level of bone exposure and the dosage 
of intravenous BPs (e.g. zoledronate) represent specific risk factors in BRONJ that may determine the success of a 
recommended conservative treatment. Additionally, the NTX levels might be able to be a prognostic factor for the 
conservative treatment of BRONJ; additional research is necessary.
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Introduction
Bisphosphonates (BPs) are a class of drugs derived from 
pyrophosphates, which are endogenous inorganic re-
gulators of mineralization. The substitution of oxygen 
atoms in the basic pyrophosphate chain with carbon in-
hibits osteoclasts, causing reduced bone resorption (1,2). 
BPs are very effective in the management of malignan-
cy-related hypercalcemia and skeletal events associated 
with multiple myeloma, bone metastasis from breast 
cancer and prostate cancer, and osteoporosis (3). Howe-
ver, nitrogen-containing BPs are also associated with an 
increased risk of developing osteonecrosis of the jaw; 
zoledronate and pamidronate, drugs used commonly to 
stabilize metastatic cancer deposits in the bone, appear 
to be particularly closely linked to this phenomenon (4). 
Many cases of bisphosphonate-related osteonecrosis 
of the jaw (BRONJ) have been reported globally and, 
although the incidence of BRONJ is generally thought to 
be low, its occurrence impacts negatively on oral hygiene 
and patient quality of life (QOL). BRONJ is extremely 
intractable because neither the pathogenic mechanism 
nor a standard therapy for BRONJ has been established. 
Conventional therapy bears similarity to that for osteo-
myelitis of the jaw, involving active surgical resection 
(e.g. sequestrectomy) and hyperbaric oxygen treatment 
(5). However, the American Association of Oral and 
Maxillofacial Surgeons (AAOMS) and the Japanese 
Society of Oral and Maxillofacial Surgeons (JSOMS) 
now recommend a more conservative treatment strategy 
(1,6), such as the use of antibiotics, gargling with anti-
microbial agents, and local irrigation and surgical debri-
dement, while there are some cases that are resistant to 
these treatment. Additionally, BRONJ risk fctors were 
categorised as drug-related, local and demographic or 
systemic factors (1). Other medications, such as steroids, 
thalidomide and other Anti-cancer drugs, were thought 
to be risk factors, however no measurable associations 
were identified. We therefore performed a clinical analy-
sis of the risk factors evident in intractable BRONJ cases 
following a recommended conservative treatment in our 
department.
Patients and Methods
Between April 2004 and May 2011, 52 patients (8 males, 
44 females) were referred to our hospital for prevention 
or treatment of BRONJ. Our protocol adhered strictly to 
AAOMS guidelines, which necessitate the identification 
of the following: 1) Exposed bone in the maxillofacial 
region over a period of 8 weeks; 2) current or previous 
treatment using BPs; and 3) no prior history of radiation 
therapy to the jaw region.
The treatment objectives for patients with an establis-
hed diagnosis of BRONJ are to eliminate pain, control 
infection of the soft and hard tissue, and minimize the 
progression or occurrence of osteonecrosis. The staging 
of BRONJ was performed according to AAOMS 2009 
recommendations, which suggest that surgical debride-
ment and/or a resection approach are indicated only in 
patients with advanced stage disease (either stage 3, or 
stage 2 disease that is resistant to antibiotics). We re-
trospectively reviewed the age, gender, affected site, 
BRONJ staging, type of pharmaceutical BP preparation, 
reason for taking BPs, duration of BP use, method of ad-
ministration, presence of withdrawal, bone denudation 
areas, risk factors (namely: diabetes mellitus, steroids, 
anticancer drugs, smoking, drinking, and periodontal 
disease), history of dental surgical treatment related to 
BP medication and any previous treatment for BRONJ 
based on clinical records, intraoral photography, and ra-
diological assessment at the initial diagnosis. We selec-
ted cases (stages 0–3) that were treated conservatively, 
including by instruction in oral hygiene, administration 
of antibiotics, antimicrobial mouth rinses, local irriga-
tion, and sequestrectomy according to the BRONJ gui-
delines defined by the AAOMS and the JSOMS. The 
cure period was defined as the time taken for mucosa to 
completely cover necrotic tissue and exposed bone. Fur-
thermore, we investigated the cure period for patients 
who were initially diagnosed as stages 1–3 with bone 
exposure using the Kaplan–Meier method. The levels of 
urinary cross-linked N-terminal telopeptide of type 1 co-
llagen (NTX) were measured during a periodic check-up 
in osteoporosis management after BRONJ diagnosis. A 
group of 13 patients on BP therapy for osteoporosis for 
>6 months but with no occurrence of BRONJ were used 
as a control group for the NTX measurements, and were 
also monitored during a periodic check-up for osteopo-
rosis management.
Statistically significant differences were tested using the 
Mann-Whitney-U test.
Results
The 52 patients selected were all referred to our hospital 
for intraoral symptoms such as swelling, pain, pus dis-
charge, and bone denudation. Of these, 19 cases (36.5%) 
were stage 0, five cases (9.6%) were stage 1, 22 cases 
(42.3%) were stage 2 and six cases (11.5%) were stage 
3. When the stage distribution was analyzed according 
to age, we found the greatest proportion of patients to 
be in their 70’s (19 patients). This was similar to the 
distribution of patients treated with BPs, as in previous 
reports. Stage 3 disease was present only in patients 
over 60 years of age. Furthermore, we investigated the 
cure period for patients who were initially diagnosed as 
stages 1–3 with bone exposure using the Kaplan–Meier 
method. In this analysis, the cure period was defined as 
ending at the point when no bone exposure remained. 
In terms of the therapeutic ratio, there were no major 
differences between women and men. The cure period 
ranged from 1–24 months, and the median cure period 
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ve treatment. Additionally, in six patients (11.5%), BPs 
were combined with anticancer drugs. Five of the nine 
cancer patients died of other illnesses during the course 
of BRONJ treatment. Furthermore, we investigated the 
presence of other risk factors for BRONJ; diabetes me-
llitus was observed in four refractory patients (22.2%), 
but no diabetic patients were found among the resolved 
cases. Steroid therapy in particular has been reported to 
have negative effects on bone tissue (7), but when we 
analyzed patients treated using BPs in combination with 
corticosteroids, three patients showed complete resolu-
tion of the disease. As for smoking and drinking, the-
re were no significant differences between refractory 
and resolved cases. Among the refractory cases, 66.6% 
showed poor oral hygiene, including deposition of pla-
que and the presence of periodontal disease. The period 
of BP treatment for all cases ranged from 1–130 months 
(stage 0–3), with a mean of 46.4 months. The mean du-
ration of BP administration until onset of BRONJ was 
41.6 months (7–70 months) in resistant cases; however, 
there were no significant differences compared with 
patients showing good healing. BPs were withdrawn 
from one patient (3%) exhibiting good healing, whereas 
BPs were not withdrawn from seven refractory patients 
(38.9%). In these seven patients, we preferred to use BPs 
for treatment of cancer bone metastases under consulta-
tion with a physician.
Furthermore, we investigated and evaluated the range 
of bone exposure area during our initial consultation. 
We evaluated the area of bone exposure according to 
the number of teeth, using X-rays, medical records, and 
intraoral photographs. Refractory patients showed a sig-
nificantly wider bone exposure range compared with 
patients in whom healing was good. The average bone 
exposure range was 2.6 teeth across all patients, 1.6 tee-
th (range 1–2) for those showing good healing, and 3.4 
teeth (range 1–7) for refractory patients (Table 1).
Data on urinary NTX levels were collected from the phy-
sicians that had initially prescribed the BP drugs. Gene-
rally, daily variation of the urinary marker is large and 
is inferior in plasticity, whereas the measurement error 
is small and the serologic marker is superior in plasti-
city. The urinary NTX levels in the treatment-refractory 
group were low (19.2–54 nmol BCE/mmol Cr (mean: 
30.8 ± 12.6)) compared with the control (mean: 39.7 ± 
19.7) and remission (mean: 41.1 ± 22.3) groups, although 
these differences were not significant (P = 0.11). Our 
data showed that there were no significant differences in 
NTX levels between patients with no BRONJ or BRONJ 
stage 0 and those with stage 1–3 disease, although NTX 
levels tended to be lower in those patients refractory to 
conservative treatment than in patients showing good 
healing (Fig. 2).
was seven months. Of the 33 patients included in this 
group, seven (21.2%) either died or dropped out during 
the treatment period and the cure rate of the remainder 
was 61.5% (16 patients) (Fig. 1). Therefore, we inves-
tigated intractable cases for which the cure period was 
longer than 7 months or in which the disease progressed 
to a higher stage during conservative treatment.
Fig.1. Kaplan-Meier curve showing the time after diagnosis un-
til no further bone exposure was evident.
According to stage distribution, many intractable cases 
were classified as stage 2. Of the intractable cases, eight 
(44%) developed BRONJ following tooth extraction, and 
seven of these developed BRONJ due to tooth extraction 
without withdrawal of BPs. The single remaining case 
(1.9%) developed BRONJ following tooth extraction 3 
months after withdrawal of alendronate. The affected 
site was most often (66.7%) in the mandible in patients 
with stage 0–3 disease. In the intractable cases, the inci-
dence of lesions in the maxilla, mandible and both jaws 
was 16.7%, 72.2% and 11.2%, respectively.
BPs were administered by injection in 23% of stage 0–3 
cases and in 50% of intractable cases. In all stage 0–3 
cases, the BP administered was a second-generation 
drug (alendronate) in 50% of cases, whereas the remain-
der were treated with third-generation drugs in the or-
der of frequency risedronate>zoledronate>minodronat
e. Of the patients that were refractory to conservative 
treatment, 44% were treated using zoledronate, whereas 
for alendronate this figure was 33%. Additionally, 80% 
of patients administered zoledronate were found to be 
refractory to conservative treatment.
Among all BRONJ cases (stage 0–3), the reason for ad-
ministering BPs was osteoporosis in 39 patients (75%), 
treatment of bone metastasis in 21% (breast cancer: 7 
patients, thyroid cancer: 1 patient, stomach cancer: 2 pa-
tients, rectal cancer: 1 patient), and other reasons in two 
patients (4%). Of the refractory cases, those administered 
BPs for cancer bone metastases included nine patients 
that accounted for half of those resistant to conservati-
e25
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Caracteristics Stage(0~3) (n=52) Remission (n=15) Persistent (n=18)
n % n % n %
Age          
              
BRONJ stage
              
               
Affected jaw
BPs type
Bisphosphonate 
preparations
Bone disease
Concurrent medica-
tion           
          
Other risk factor of 
BRONJ
Treatment duration 
until onset (month)
               
　　　
BP medication
Bone exposure 
range (The number 
of the teeth ）
                Mean           
Range
Mean
Range
stage 0
stage 1
stage 2
stage 3  
Mandible
Maxilla
Both
Intravenous
Oral
Alendronate
Risedoronate
Minodoronate
Zoledronate
Osteoporosis
Bone metastasis         
Multiple myeloma
Anticancer drugs
Corticosteroids
Periodontitis
Diabetes
Alcohol use
Smoking
Mean
Range
Continuation
Discontinuation
72.3
35-88
19
5
22
6 
35
14
3
12
40
26     
15     
1      
10
39
11
2
6
6
12
2
2
1
46.4
1-130
9
43
2.6
1-7
36.5
9.6
42.3
11.5
67.3
26.9
5.8
23
77
50
28.8
2
19.2
75
21
4
11.5
11.5
23
4
4
2
17.3
82.7
74
58-88
-
3
10
2
10
5
0
3
12
 
9     
4      
0      
2      
13
2
0      
1
5
3
0
2
1
45.7
12-90
1
14
1.6
1-2
20.0
66.7
13.3
66.7
33.3
0
20
80
60
26.7
0
13.3
87
13
0
7
33.3
20
0
13
7
6.7
93.3
73.4
45-86
-
2
12
4
13
3
2
9
9            
6
3
1 
8
 
9 
9
0
5
0
12
4
1
1
41.6
7-70
7 
11
3.4
1-7
11.1
66.7
22.2
72.2 *
16.7 *
11.1
50.0 *
50.0
33.3
16.7
5.6
44.4 *
50
50
0
27.8 *
0
66.6 *
22.2
5.6
5.6
38,9 *
61.1
Statistic analysis performed using c2 test or Fisher exact test and Cox proportional hazards model. *: P < 0.01 
Table 1. Statistical analysis results between patient characteristics and outcome of the conservative treatment.
Discussion
BRONJ is a recognized side effect of treatments using 
BPs and involves osteonecrosis of the jaw caused by di-
sordered wound healing after invasive dental treatment 
such as tooth extraction, periodontal surgery, endodon-
tic treatment, or periodontal treatment. Currently, there 
is no definitive preventative method and no universally 
recommended treatment modality. Since osteonecrosis 
of the jaw was first reported as a serious side effect of 
BP treatment by Marx (4) in the United States in 2003, 
similar findings have been reported elsewhere (1,2). In 
Europe and the United States, more than 2,500 cases of 
BRONJ have been reported (8), with the majority being 
in patients receiving BP injections to treat cancer, and a 
study by the AAOMS showed that 94% of 364 BRONJ 
patients received such injections, whereas BRONJ cau-
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sed by oral administration accounted for only 4.7% 
(1). However, the results of a nationwide survey by the 
JSOMS in 2007 (1) indicated that injections accounted 
for only 73.3% of BRONJ cases whereas disease arising 
following oral administration was much more common 
in Japan than in the United States. In our study, 23% 
of patients with stage 0–3 disease received injections 
at stage 1 or higher, and exposed bone was observed in 
12 patients (33%) treated using injections. Regarding 
oral medication, many more cases of BRONJ induced 
by alendronate were observed than reported in previous 
studies (1,9,10). In our study, BPs were administered by 
injection in 50% of refractory patients. In Japan, a po-
tentially greater number of BRONJ patients are treated 
using oral medication than reported in the United Sta-
tes. According to an investigation by JSOMS, cases of 
BRONJ developing following BP injection have been 
reported to be more severe than those following oral ad-
ministration (3). Our survey found more BRONJ cases 
induced by oral medication than previous reports, while 
half of the refractory cases were induced by BP injection 
and tended to respond poorly to conservative treatment. 
More women (44 patients, 85%) than men (8 patients, 
15%) tended to suffer from BRONJ, as expected given 
the indications for BP treatment. Furthermore, we found 
most cases to be in patients over 60 years of age, so a 
high percentage of senior citizens were recognized in 
our study population, consistent with a report by the 
American Dental Association (1).
Consistent with previous studies, we found that BRONJ 
most commonly affects the lower jaw. This is because 
the lower jaw, like other bones such as the femur, is su-
rrounded by cortical bone, but the teeth anchored in this 
bone extend into the bone marrow from the oral cavity 
providing periodontal microorganisms a path of ingress 
to that site. Furthermore, the oral mucosa is thin and sus-
ceptible to injury caused by, for example, dentures. Bone 
metabolism in alveolar bone is estimated to be higher 
than that of long bones (~10 times that of the tibia and 
3–5 times that of the inferior border of the mandible) 
making it more susceptible to agents affecting remode-
ling (11). Therefore, a large uptake of BPs coupled with 
an enhanced environment for further bone metabolism 
facilitates the development of BRONJ (12). BRONJ oc-
curs most commonly following tooth extraction (13,14). 
Indeed, it was estimated that 108 of 263 cases (41.1%) 
were associated with tooth extraction (6) and our own 
study contains a large number of patients that developed 
BRONJ after tooth extraction, including eight that were 
refractory for BRONJ. According to AAOMS guideli-
nes, it is recommended to withdraw BP medications for 
three months or more from any patient requiring invasi-
ve surgery (e.g. tooth extraction) that has been on such 
medication for 3 years or more. However, this ‘washout’ 
period for BPs differs for patients with complications 
such as diabetes and for those taking steroids. Currently, 
if patients have additional risk factors, there are no clear 
criteria for withdrawal of BPs, and the washout period 
chosen is at the discretion of the attending physician. In 
our department, a refractory case with a history of oral 
alendronate for seven months developed BRONJ even 
after three months of withdrawal, following a tooth ex-
traction. That patient exhibited mild periodontal disease 
as a risk factor, but no specific systemic risk factors. In 
another case of BRONJ, we identified a denture-related 
injury but the onset of BRONJ was otherwise sponta-
neous and idiopathic. Several risk factors have been 
proposed for BRONJ (15), although many of these are 
contentious. We found no significant link between res-
ponsiveness to treatment and the existence of diabetes 
or the use of steroids, tobacco or alcohol. However, pa-
tients with poor oral hygiene were more frequently re-
fractory to treatment and we therefore emphasized the 
importance of oral hygiene, including scaling, from the 
outset of BRONJ treatment.
According to the AAOMS, a combination of anticancer 
drugs is also a risk factor in BRONJ. In our study, 28% of 
the refractory cases were found to have taken combined 
anticancer drugs so, if a combination of anticancer drugs 
is noted when performing conservative treatment, we 
suggest that the cure rate may be diminished. It has also 
been reported that the incidence of BRONJ in patients 
treated using BPs for 4–12 months was 1.5%, compared 
with 7.7% for those treated for 37–48 months (15-18), 
suggesting that the risk of BRONJ onset increases accor-
ding to the duration of BP administration. However, our 
results demonstrate that the period of BP administration 
has no significant bearing on treatment responsiveness. 
Additionally, it has been reported that the relationship 
between the type of BP and the incidence of BRONJ is 
not clear. In our department, second generation BPs such 
as alendronate accounted for half of all BRONJ patients 
(stage 0–3). BRONJ patients accounted for less than 1 
Fig. 2. Urinary levels of bone resorption marker cross-linked 
amino-terminal telopeptide of type I collogen (NTX). The mean 
of the Persistent group was lower than that of the control and 
remission group but there was no significance (P = 0.11).
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per 100,000 person-years in a European osteoporosis 
working group study (19), but it has also been reported 
that there is a high rate (4%) of BRONJ when BPs are 
administered orally (20).
In any case, the number of patients taking oral BPs has 
increased and, as a result, we must be cognizant that the 
number of BRONJ cases will consequently also increa-
se, even though the incidence rate is less than that for 
BP injection. In this study, alendronate accounted for 
33% of refractory cases, suggesting that a large num-
ber of BRONJ cases induced by oral BPs are resistant to 
conservative treatment. Additionally, 80% of all patients 
treated using zoledronate showed resistance to conser-
vative treatment, so it was concluded that injection of 
BPs has a high BRONJ incidence rate compared with 
oral medication and that the duration of conservative 
treatment is likely to be longer for resistant cases.
Regarding the reasons for BP administration, 37 cases of 
BRONJ arose in patients treated for osteoporosis (71%). 
However, among refractory cases, 50% were treated 
using BPs for cancer bone metastasis. We conclude that 
the use of combination chemotherapy is a prognostic 
factor in the treatment of bisphosphonate-related osteo-
necrosis of the jaw, and thus recommend that it is neces-
sary to carefully consider potential resistance to conser-
vative treatment when planning the use of conservative 
therapy in patients receiving combination chemotherapy. 
It may also be necessary to consider aggressive surgical 
treatment in preference to conservative treatment in or-
der to maintain QOL and shorten the healing period.
It was previously reported that serum C-terminal telo-
peptide cross-linked type I collagen was reduced in pa-
tients diagnosed with BRONJ, and that, in this patient 
group, invasive dental surgery contributes to an increa-
sed risk of BRONJ (21). Urinary NTX is effective in 
monitoring the effect of BPs and bone metabolism sta-
tus (22) and we suggest that it may also be a predicti-
ve marker for cases resistant to conservative treatment. 
Additionally, in those resistant cases where urinary NTX 
was high, interpretation was complicated by the exis-
tence of one or more other risk factors, such as the use 
of combination chemotherapy. Therefore, while NTX 
might be useful in predicting the convalescence period, 
it should not be used in isolation to make prognostic de-
cisions. Where conservative treatment fails, aggressive 
surgical treatment can be applied as an alternative with 
good results (23), although some reports suggest that 
full coverage with soft tissue and the use of a wound 
closure approach are necessary if surgical treatment is 
performed (24). The decision regarding the area of bone 
to be resected in cases of BRONJ is also controversial; 
it has been considered by some to be necessary to cut 
bone to admit a fluorescent moiety detectable by ultra-
violet irradiation after the administration of doxycycli-
ne, which reportedly incorporates into new bone (25). In 
light of our current results, cases that are expected to be 
resistant to the conservative treatment recommended by 
the AAOMS should be considered for more aggressive 
surgical intervention with careful consideration of the 
clinical features. However, further research is required 
to identify more prognostic markers such as NTX that 
could facilitate the identification of those cases that are 
likely to be most resistant to conservative treatment.
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